市場調查報告書
商品編碼
1262761
2023-2030年全球稀有糖市場Global Rare Sugar Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內(2023 年至 2030 年),全球稀有糖市場的複合年增長率為 4.2%。
單醣及其衍生物是自然界中含量極少的稀有醣類。 單醣有50多種,但大量存在的只有7種。 這些糖是 L-阿拉伯糖、D-核糖、D-木糖、D-果糖、D-甘露糖、D-半乳糖和 D-葡萄糖。 其餘糖為稀有糖,其甜度約為普通糖的70%。
稀有糖被用作合成用於抗病毒和抗癌藥物的核甘類似物的組成部分。 他們準備使用發酵和□促轉化等有機過程來製造相同的化合物。
儘管稀有糖的天然豐度較低,但它們具有許多重要用途,例如用作抗病毒藥物的成分。 此外,由於其低血糖指數,它被用作低熱量甜味劑。 由於其免疫抑制特性,它也被用作抗炎劑。
攝入稀有糖有助於為註重健康的消費者帶來益處。 例如,D-甘露糖單醣可減弱胰島素反應並降低對血糖水平的影響,使其成為各種功能性食品和飲料中天然糖的更好替代品。 它還具有低血糖指數,因為它在胃腸道中被緩慢吸收,而不是像葡萄糖那樣在肝臟中積累,這推動了稀有糖市場的增長。 在法國和英國,政府通過選擇性徵稅、產品改進、預包裝標籤等方式減少食糖消費,預計將促進市場擴張。 這些努力支持世衛組織 2015-2020 年歐洲食品和營養行動計劃的政策建議,以營造更健康的食品環境。
大大製約稀有糖市場增長的因素預計是通過嚴格的標籤和製造方法建立嚴格的法規和合規性來保護消費者的利益。
例如,2019 年 4 月,美國食品和藥物管理局製定了用於營養和補充劑的阿洛酮糖卡路裡數量指南。 根據該法律,要符合低糖或低熱量產品的資格,稀有糖的製造商必須遵守嚴格的規定。 稀有糖市場預計將面臨來自這些因素的挑戰。
COVID-19 分析包括 COVID 前情景、COVID 情景、COVID 後情景、價格動態(與 COVID 前情景相比,大流行期間和之後的價格變化)、供需譜(需求和供應變化由於貿易限制、封鎖和後續問題);我們還計劃解釋製造商的舉措。
The global rare sugar market reached US$ XX million in 2022 and is projected to witness lucrative growth by reaching up to US$ XX million by 2030. The market is growing at a CAGR of 4.2% during the forecast period (2023-2030).
Monosaccharides and their derivatives, which are present in nature in incredibly small amounts, are rare sugars. There are over 50 different types of simple sugars, but only seven are found in significant quantities. These sugars are L-arabinose, D-ribose, D-xylose, D-fructose, D-mannose, D-galactose and D-glucose. The remaining sugar is rare and has a sweetness level of 70% of regular sugar.
The building blocks to synthesize nucleoside analogs, which are used as antiviral and anti-cancer agents, use rare sugars. They are prepared to create the same compound using organic processes like fermentation or enzyme conversion.
Despite their low natural abundance, rare sugars have many important applications, including their use as components in antiviral medications. Furthermore, because of their low glycemic index, they are used as low-calorie sweeteners. They also serve as anti-inflammatory drugs because of their immunosuppressive qualities.
The consumption of rare sugar helps in providing benefits for health-conscious consumers. For instance, D-Mannose monosaccharide significantly blunts insulin response and reduces the impact on blood sugar level, thus making it a better alternative as natural sugar in different functional food and beverages. It is also not stored in the liver like glucose and is absorbed more slowly in the gastrointestinal tract, thus accounting for a lower glycemic index, propelling the growth of the rare sugar market. It is anticipated that national government initiatives in France and the U.K. to reduce sugar consumption through selective taxation, product reformulations and explanatory front packaging labels will aid market expansion. These initiatives support WHO's 2015-2020 European Food and Nutrition Action Plan's policy recommendations for fostering a healthier food environment.
It is anticipated that a significant restraint on the growth of the rare sugar market will come from stringent regulations and compliances designed to safeguard consumers' interests through strict labeling and manufacturing practices.
For instance, in April 2019, the U.S. Food and Drug Administration established guidelines on the number of calories in allulose for nutrition and supplementation. To qualify as low-sugar or low-calorie products under this legislation, manufacturers of rare sugar must adhere to stringent regulations. The rare sugar market is anticipated to face challenges due to such factors.
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
The global rare sugar market is segmented based on product, end-user and region.
D-Mannose segment in the rare sugar market is expected to hold a significant global market share. D-mannose is often sold as a dietary supplement for lowering the incidence of UTIs. According to research, augmented D-mannose may be a potential alternative or supplemental therapy, particularly as a preventive for recurrent UTIs. D-mannose, when discharged in urine, may prevent Escherichia coli, the principal causative bacterium of UTIs, from adhering to urothelium and causing infection. D-mannose may also prevent some types of bacteria from adhering to the urinary system walls and causing illness.
D-mannose may be safe for most individuals for up to 6 months when taken orally. Nonetheless, it has the potential to cause diarrhea and nausea.
Due to the growing demand for D-mannose treating UTIs, many manufacturers are launching new probiotic products with the respective compound. For instance, Labiana pharmaceuticals launched Precyst, a new food supplement to help the well-being of the urinary system in women, on December 16, 2020. The product comprises two natural substances with synergistic effects: D-Mannose and cranberry extract.
Furthermore, Utiva launched a new line of urinary tract health and wellness products on March 11, 2021. The new product line comprises point-of-need solutions named Utiva UTI Control 36PAC Cranberry Pills, Probiotic Power Supplements and D-Mannose Attack, some effective wellness triumvirates capable of preventing urinary tract infections.
According to the International Trade Centre, Japan imported the most chemically pure sugars in 2021, totaling 62,314 tons. China also imported 10,120 tons of chemically pure sugar.
Global firms are developing and entering this market area in this region through collaboration and partnership with others to expand their regional growth. For instance, GNC Holdings Inc engaged in a relationship with a Hong Kong-based Chinese e-Commerce firm in February 2019 to expand the product range of supplements such as Now D-Mannose and Source Naturals D-Mannose in China's supplement industry.
EIAs for Anhui Tiankai's nutritional supplements healthy industry project and functional and nutritional healthy food project were made public on May 17, 2021, before approval by the Government of Quanjiao County. Both projects will include allulose production lines with a total capacity of 2,500 t/a.
Baolingbao Biology Co., Ltd. stated in a Q&A forum for investors in November 2021 that the business has made full preparations for future domestic licensing of the usage of psicose.
Earlier on August 25, BLB announced the launch of a 30,000 t/a psicose (dry basis) project to prepare for the anticipated psicose market in China and meet demand from abroad markets. The project has a total investment of US$ 58.82 million (RMB380 million) and a construction span of two years; it is now in the planning stages. These development operations will generate new opportunities for regional market expansion.
The major global players in the market include Ingredion Incorporated, Nestle, Avantor, Inc, Tate & Lyle, Jarrow Formulas Inc, Shijiazhuang Huaxu Pharmaceutical Co.,Ltd, Sanwa Starch Co., Ltd., Zhangjiagang Sipu Biochemical Co., Ltd, Sweet Cures Limited, and Matsutani Chemical Industry Co. Ltd.
The global rare sugar market report would provide approximately 53 tables, 51 figures and 202 pages.